Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US6255112

Title:Regulation of hematopoietic stem cell differentiation by the use of human mesenchymal stem cells
Inventors:Thiede, Mark A.; Forest Hill, MD, USA
Summary:This invention relates to a process of producing osteoclasts in vitro. Described herein are methods of inducing hematopoietic stem cells to differentiate into osteoclasts by culturing hematopoietic stem cells with human mesenchymal stem cells, preferably without exogenous cytokines, such that the differentiation of the mesenchymal stem cells into osteoblasts was found to inhibit the differentiation of hematopoietic stem cells into osteoclasts. Further disclosed are methods by which the hematopoietic stem cells can be genetically engineered to carry genes of interest, particularly for the expression of physiologically active proteins, such that, in the presence of mesenchymal stem cells, the transduced cells carry the new genetic material and express gene products which can be used to modulate bone resorption.
Abstract:The invention relates to the induction of hematopoietic stem cells to differentiate into osteoclasts by culturing hematopoietic stem cells with human mesenchymal stem cells, and, in a preferred embodiment, using no exogenous cytokines. Differentiation of the mesenchymal stem cells into osteoblasts inhibited the differentiation of hematopoietic stem cells into osteoclasts. In addition, hematopoietic stem cells can be genetically engineered to carry genes of interest particularly for the expression of physiologically active proteins. In the presence of mesenchymal stem cells, the transduced cells carry the new genetic material and express gene products that can be used to modulate bone resorption.
US Patent Website:Click Here for Full Text of Patent
Title Number:US6255112
Application Number:US1999000327796
Date Filed:08/06/1999
Date Published:03/07/2001
Assignee:Osiris Therapeutics, Inc., Baltimore, MD, USA


 
Copyright © 2007 The Institute for Cellular Medicine  6/13/2021